Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mars bought Heska

6/13/23 HSKA

Qiwi will withdraw from assets in Russia to maintain a listing on the Nasdaq

6/9/23 QIWI

Sollers plans to start producing electric cars based on the Atlant and Argo LCVs in 2024

6/9/23 SVAV

Shareholders of Rosseti Centere approved dividends for 2022

6/9/23 MRKC

Shareholders of Rosseti Center and Volga Region approved dividends for 2022

6/9/23 MRKP

Owners of Noventiq receipts can receive up to three shares of Softline JSC

6/9/23 SFTL

Permission of the Head of VSMPO - AVISMA was prolonged till the end of the year

6/9/23 VSMO

Irkut opens center for SSJ100 electronic components repair

6/9/23 IRKT

IDGC of Urals will change its name to Rosseti Urals

6/9/23 MRKU

Shareholders of IDGC of Urals approved dividends for 2022

6/9/23 MRKU